• two routes
  • metabolism

VYZULTA®: One active molecule, two routes1†

  • Intraocular pressure (IOP) is a major modifiable risk factor for glaucoma progression
  • Reduction of IOP reduces risk of glaucomatous visual field loss
  • VYZULTA® is thought to lower IOP by increasing outflow of aqueous humorthrough both uveoscleral and trabecular meshwork routes

VYZULTA® is not indicated to reduce the risk of glaucoma progression or glaucomatous visual field loss.

† Clinical significance unknown.